Revolution Medicines RVMD

$ 44.17 0.71%

Quarterly report 2024-Q2
added 08-07-2024

Revolution Medicines Balance Sheet 2011-2024 | RVMD

Annual Balance Sheet Revolution Medicines

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-608 M	-97.2 M	-41.9 M	-	-16.5 M	-69.4 M	-9.08 M	-	-	-	-	-	-
Long Term Debt	80.6 M	57.4 M	60.4 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	7.37 M	6.77 M	6.21 M	3.67 M	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	24.9 M	43.4 M	2.95 M	-	-	-	-	-	-
Total Current Liabilities	144 M	62 M	60.4 M	47.2 M	-	-	-	-	-	-	-	-	-
Total Liabilities	236 M	127 M	135 M	92.7 M	68 M	73.9 M	10.5 M	-	-	-	-	-	-
Deferred Revenue	-	4.46 M	12.4 M	12.1 M	17.1 M	16.8 M	-	-	-	-	-	-	-
Retained Earnings	-1.14 B	-701 M	-453 M	-266 M	-157 M	-110 M	-67.9 M	-	-	-	-	-	-
Total Assets	2.06 B	812 M	738 M	567 M	221 M	171 M	15.1 M	-	-	-	-	-	-
Cash and Cash Equivalents	696 M	161 M	108 M	104 M	16.7 M	-	-	-	-	-	-	-	-
Book Value	1.83 B	685 M	603 M	475 M	153 M	96.7 M	4.53 M	-	-	-	-	-	-
Total Shareholders Equity	1.83 B	685 M	603 M	475 M	-153 M	-108 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Revolution Medicines

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	79.1 M	79.9 M	80.6 M	57.1 M	57.5 M	57.7 M	57.4 M	58.2 M	58.9 M	59.6 M	60.4 M	26.8 M	27.6 M	28.3 M	29 M	29 M	29 M	29 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	190 M	183 M	236 M	147 M	143 M	121 M	127 M	144 M	134 M	132 M	135 M	96.8 M	89 M	89.1 M	92.7 M	92.7 M	92.7 M	92.7 M	68 M	68 M	68 M	68 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	1.43 M	4.46 M	9.69 M	9.69 M	11.4 M	12.4 M	12.7 M	8.34 M	9.96 M	12.1 M	12.1 M	12.1 M	12.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.39 B	-1.25 B	-1.14 B	-976 M	-868 M	-769 M	-701 M	-645 M	-572 M	-510 M	-453 M	-400 M	-347 M	-303 M	-266 M	-266 M	-266 M	-266 M	-157 M	-157 M	-157 M	-157 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	1.81 B	1.91 B	2.06 B	984 M	1.07 B	1.07 B	812 M	826 M	633 M	683 M	738 M	735 M	774 M	812 M	567 M	567 M	567 M	567 M	221 M	221 M	221 M	221 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	276 M	288 M	696 M	358 M	380 M	427 M	161 M	179 M	106 M	97.7 M	108 M	129 M	196 M	352 M	104 M	104 M	104 M	104 M	16.7 M	16.7 M	16.7 M	16.7 M	69.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	1.62 B	1.73 B	1.83 B	837 M	931 M	952 M	685 M	681 M	499 M	551 M	603 M	638 M	685 M	723 M	475 M	475 M	475 M	475 M	153 M	153 M	153 M	153 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	1.62 B	1.73 B	1.83 B	837 M	931 M	952 M	685 M	681 M	499 M	551 M	603 M	638 M	685 M	723 M	475 M	475 M	475 M	475 M	-153 M	-153 M	-153 M	-153 M	-108 M	-	-	-	-67.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency